短腸症候群（SBS）の世界市場：現状分析と予測（2021年～2027年）

世界の短腸症候群（SBS）の市場規模は、2021年から2027年の予測期間中に、約27％のCAGRで成長すると予測されています。市場の成長を後押しする主な要因には、患者数の増加、医療費の増加、医療分野の急速な改善による認識の高まり、研究開発の促進などが挙げられます。

当レポートでは、世界の短腸症候群（SBS）市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、製品・流通チャネル・地域別の分析、および企業プロファイルなどを提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 制限
• ステークホルダー
• レポートで使用される通貨

第2章 調査手法または前提条件

• 短腸症候群（SBS）市場の調査プロセス
• 短腸症候群（SBS）市場の調査手法
• 予測方法
• 回答者プロファイル
• 短腸症候群（SBS）市場調査の主な目的

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 世界の短腸症候群（SBS）市場へのCOVID-19の影響

第6章 世界の短腸症候群（SBS）市場の収益（2019年～2027年）

第7章 製品別の市場洞察

• グルカゴン様ペプチド-2（GLP2）
• 成長ホルモン
• グルタミン
• その他

第8章 流通チャネル別の市場洞察

• 病院薬局
• 小売薬局
• オンライン販売

第9章 地域別の市場洞察

• 北米の短腸症候群（SBS）市場
  • 米国
  • カナダ
  • その他の北米
• 欧州の短腸症候群（SBS）市場
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋の短腸症候群（SBS）市場
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋
• その他の地域の短腸症候群（SBS）市場

第10章 短腸症候群（SBS）市場力学

• 市場促進要因
• 市場抑制要因
• 影響分析

第11章 短腸症候群（SBS）市場機会

第12章 短腸症候群（SBS）市場動向

第13章 法律および規制の枠組み

第14章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業プロファイル

• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Zealand Pharma A/S
• OxThera
• VectivBio AG
• 9 Meters Biopharma, Inc.
• Nutrinia Ltd.
• Hanmi Pharm.Co., Ltd.
• Pharmascience, Inc.
• Nestle

第18章 免責事項

The short bowel syndrome market is expected to register a CAGR of around 27% over the period of 2021-2027. Short bowel syndrome (SBS) is a metabolic disorder caused by dysfunction or elimination of the small intestine due to surgery for gastrointestinal disorders. The side effects of this syndrome include malabsorption, diarrhea, steatorrhea, water and electrolyte imbalances, and malnutrition. Initial treatment for short bowel syndrome includes maintaining good nutrition, maximizing the absorption area of the remaining intestine, and avoiding complications. The growing number of cases of short bowel syndrome is mainly due to an increase in diseases related to the intestine, genetic inheritance of SBS, etc. For instance, according to the National Institute of Diabetes and Digestive & Kidney Diseases, every year, short bowel syndrome affects nearly 3 out of every million people. Furthermore, the short bowel syndrome market is also anticipated to grow on account of the growing healthcare expenditure, rapid improvements in the field of healthcare have increased awareness regarding this disease, and state government with nonprofit organizations provide special incentives to market players as it promotes research & development related to short bowel syndrome.

Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc., and Nestle are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

"Amongst Product, the Glucagon-like peptide-2 (GLP2) category accounted for the majority share in the market in 2020"

Based on product, the market is classified into glucagon-like peptide- 2 (GLP2), growth hormone, glutamine, and others. Amongst products, the GLP2 category accounted for a significant share of the market. The only GLP-2 analog available on the market for the treatment of short bowel syndrome is Gattex and Revestive. the increase in prescriptions for Gattex therapy contributes to the growth of the market.

"Among Distribution Channel, the Hospital Pharmacies is expected to witness highest CAGR during the forecast period"

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and online sales. Among these, the hospital pharmacies are expected to witness a considerable CAGR during the forecast period due to an increase in patients in hospital settings and rising implementation of therapy. Moreover, patient preference for affordable and more expensive parenteral nutrition along with prescription drugs contributes to a large share of this segment.

"North America to witness significant growth during the forecast period"

For a better understanding of the market dynamics of the short bowel syndrome market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the short bowel syndrome in 2020 owing to due to the revenue generated by Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

Global short bowel syndrome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Short Bowel Syndrome Market
• 2.2. Research Methodology of the Short Bowel Syndrome Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Short Bowel Syndrome Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL SHORT BOWEL SYNDROME MARKET COVID-19 IMPACT

6 GLOBAL SHORT BOWEL SYNDROME MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY PRODUCT

• 7.1. Glucagon-like Peptide-2(GLP2)
• 7.2. Growth Hormone
• 7.3. Glutamine
• 7.4. Others

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospital Pharmacies
• 8.2. Retail Pharmacies
• 8.3. Online Sales

9 MARKET INSIGHTS BY REGION

• 9.1. North America Short Bowel Syndrome Market
  • 9.1.1. United States
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe Short Bowel Syndrome Market
  • 9.2.1. Germany
  • 9.2.2. France
  • 9.2.3. United Kingdom
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia Pacific Short Bowel Syndrome Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Australia
  • 9.3.5. Rest of Asia Pacific
• 9.4. Rest of World Short Bowel Syndrome Market

10 SHORT BOWEL SYNDROME MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 SHORT BOWEL SYNDROME MARKET OPPORTUNITIES

12 SHORT BOWEL SYNDROME MARKET TRENDS

13 LEGAL & REGULATORY FRAMEWORK

14 DEMAND AND SUPPLY SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

• 17.1. Takeda Pharmaceutical Company Limited
• 17.2. Merck KGaA
• 17.3. Zealand Pharma A/S
• 17.4. OxThera
• 17.5. VectivBio AG
• 17.6. 9 Meters Biopharma, Inc.
• 17.7. Nutrinia Ltd.
• 17.8. Hanmi Pharm.Co., Ltd.
• 17.9. Pharmascience, Inc.
• 17.10. Nestle

18 DISCLAIMER